The long term goals are to understand how the intracellular trafficking and regulated plasma membrane expression of complement receptors in human neutrophils relate to their functions in host defense and immunologic homeostasis. The investigators have previously shown that CR1 and CR3 are upregulated during PMN activation in vivo and that there are serious consequences if this is impaired, as in the deficiency of CR3 in newborns' PMNs and the removal of CR1 from PMN in the lungs of cystic fibrosis patients. They have recently focused on the intracellular storage sites of CR1 in resting PMN and the pathways of internalization of CR1 after cell activation, and they propose to continue these lines of investigation.
In Aim 1 they will immunoisolate the CR1 storage vesicles from resting PMNs using antibodies to the cytoplasmic tail of CR1 they have developed. They will determine which other proteins are stored in these vesicles, and study their mechanisms of fusion with plasma membrane fragments, focusing on the role of low molecular weight G-proteins and annexins. This should provide valuable insights into the mechanisms underlying the sequence of events in neutrophil activation by explaining how the translocation of """"""""readily mobilizable"""""""" compartments like the CR1 storage vesicles differs from the exocytosis of traditional primary and secondary granules.
In Aim 2, they will isolate the MultiVesicular Bodies (MVBs) into which CR1 is internalized after cell activation, demonstrate that they are the sties of CR1 degradation and study how CR1 internalized under different conditions (ligation, crosslinking, etc) is processed and degraded. They will also define the relationships between phosphorylation of CR1, its retention in the MultiVesicular Bodies (MVB) and degradation.
In Aim 3, they will use a Rat Basophil Leukemia (RBL) model, in which transfected CR1 has a trafficking pattern similar to that in PMN, to study how the structure of the tail of CR1 determines the regulation of its membrane expression and trafficking. CR1 mutants with truncated tails or with alterations of the putative phosphorylation site will be compared with wild type CR1 in this model. Finally in Aim 4, they will express in COS cells chimeras of CR1 mutants and FcgammaRIIa to understand why the role of CR1 in phagocytosis is primarily passive, and they will test the hypothesis that both its long filamentous extracellular domain and the lack of signalling motifs in its tail contribute to its inability to activate cells. Taken together, these studies should help us gain a better understanding of the trafficking and function of this important receptor.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI022687-11
Application #
2671836
Study Section
Special Emphasis Panel (ZRG2-ALY (01))
Project Start
1987-01-01
Project End
2001-04-30
Budget Start
1998-05-01
Budget End
1999-04-30
Support Year
11
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Chaudhuri, S; Kumar, A; Berger, M (2001) Association of ARF and Rabs with complement receptor type-1 storage vesicles in human neutrophils. J Leukoc Biol 70:669-76
Yoshida, Y; Kang, K; Berger, M et al. (1998) Monocyte induction of IL-10 and down-regulation of IL-12 by iC3b deposited in ultraviolet-exposed human skin. J Immunol 161:5873-9
Jost, C; Klickstein, L; Wetzler, E et al. (1998) Intracellular storage and regulated plasma membrane expression of human complement receptor type 1 in rat basophil leukemia cell transfectants. Blood 92:300-9
Kumar, A; Wetzler, E; Berger, M (1997) Isolation and characterization of complement receptor type 1 (CR1) storage vesicles from human neutrophils using antibodies to the cytoplasmic tail of CR1. Blood 89:4555-65
Tosi, M F; Zakem-Cloud, H; Demko, C A et al. (1995) Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis 172:453-61
Sengelov, H; Kjeldsen, L; Kroeze, W et al. (1994) Secretory vesicles are the intracellular reservoir of complement receptor 1 in human neutrophils. J Immunol 153:804-10
Berger, M; Wetzler, E; August, J T et al. (1994) Internalization of type 1 complement receptors and de novo multivesicular body formation during chemoattractant-induced endocytosis in human neutrophils. J Clin Invest 94:1113-25
Berger, M (1991) Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good? Clin Rev Allergy 9:119-42
Cowen, D S; Berger, M; Nuttle, L et al. (1991) Chronic treatment with P2-purinergic receptor agonists induces phenotypic modulation of the HL-60 and U937 human myelogenous leukemia cell lines. J Leukoc Biol 50:109-22
Berger, M; Wetzler, E M; Welter, E et al. (1991) Intracellular sites for storage and recycling of C3b receptors in human neutrophils. Proc Natl Acad Sci U S A 88:3019-23

Showing the most recent 10 out of 18 publications